Estradiol Gel (Divigel/Elestrin) vs Intrarosa (Prasterone): Which Works Better for Your Menopause Symptoms?

What Are These Two Drugs and Why Are Women Comparing Them?

These two therapies sit in different pharmacological categories, yet women frequently compare them because both appear on the same menopause treatment list. Estradiol gel delivers systemic estrogen through the skin. Prasterone (Intrarosa) delivers a steroid precursor directly into the vaginal canal, where it converts locally to both estrogen and testosterone without meaningful systemic absorption.

The confusion is understandable. Both are prescribed for menopause-related symptoms. Both are hormone-based. Neither is an oral pill. But calling them equivalent would be like calling a whole-body heating pad the same as a warm compress on a single joint.

A practical framework for choosing between them:

• If your main complaint is hot flashes or night sweats: Estradiol gel is the indicated choice. Intrarosa has no FDA indication for vasomotor symptoms.
• If your main complaint is painful sex or vaginal dryness only: Intrarosa is a strong first-line option. Estradiol gel will also help, but adds systemic exposure that not every woman needs or wants.
• If you have both: Some clinicians combine a low-dose local vaginal therapy with systemic estradiol gel, though data on combined regimens in women specifically are limited.

How Each Drug Works: Mechanism and Delivery

Estradiol Gel: Systemic Estrogen Through Skin

Divigel (0.1% estradiol gel, 0.25 mg to 1.5 mg daily doses) and Elestrin (0.06% estradiol gel, 0.87 g applied to upper arm daily) are topical gels that deliver 17-beta estradiol across the skin into systemic circulation. Peak serum estradiol levels are reached in 12 to 24 hours. Unlike oral estrogen, transdermal delivery bypasses first-pass hepatic metabolism, which is important for understanding clotting risk.

FDA-approved labeling confirms that transdermal estradiol gel produces steady-state serum estradiol concentrations consistent with early follicular phase levels in premenopausal women when used at recommended doses. This systemic estrogen then acts on estrogen receptors throughout the body: brain, bone, cardiovascular tissue, vaginal epithelium, bladder, and skin.

Intrarosa: Local Conversion to Estrogen and Testosterone

Prasterone is dehydroepiandrosterone (DHEA), a steroid precursor. The 6.5 mg vaginal insert (FDA approved in 2016) is placed daily in the vagina, where vaginal epithelial cells convert it intracellularly to both estradiol and testosterone via locally expressed steroidogenic enzymes. This intracrine mechanism means active hormones are produced at the tissue level, not released systemically in meaningful amounts.

Serum DHEA levels rise modestly, but published pharmacokinetic data from the FDA review show serum estradiol and testosterone concentrations remain within normal postmenopausal ranges. This is the key distinction: Intrarosa does not substantially raise systemic estrogen, so it does not carry the same uterine stimulation concern as systemic estradiol gel.

Hormone Receptor Profile Side by Side

| Feature | Estradiol Gel | Intrarosa | |---|---|---| | Active hormone | 17-beta estradiol | DHEA (converted locally to E2 + T) | | Route | Transdermal, systemic | Vaginal, local | | Estrogen receptor effect | Systemic ER-alpha and ER-beta | Local vaginal ER-alpha and ER-beta | | Androgen effect | None direct | Local testosterone (may improve libido) | | Progestogen needed? | Yes, intact uterus | Generally no | | Serum estradiol rise | Yes, measurable | Minimal |

Efficacy: What the Clinical Evidence Actually Shows

No head-to-head randomized controlled trial has compared estradiol gel directly with prasterone vaginal inserts. What exists is two separate bodies of evidence with different primary endpoints and different patient populations.

Estradiol Gel for Vasomotor Symptoms

Transdermal estradiol is the most studied route for hot flash reduction. In a large cohort study published in the BMJ, transdermal estradiol was not associated with the elevated venous thromboembolism risk seen with oral estrogens, giving it a favorable risk-benefit profile for women who need systemic therapy. The study analyzed over 80,000 women and found oral estrogen was associated with approximately a twofold increase in VTE risk, while transdermal formulations showed no statistically significant increase.

Reduction in hot flash frequency with transdermal estradiol ranges from 75 to 90 percent in placebo-controlled trials, depending on dose. Divigel 0.1% at 1.0 g daily was shown in its key trial to reduce mean weekly hot flash frequency by approximately 73 percent versus 51 percent with placebo at 12 weeks.

Intrarosa for Genitourinary Syndrome of Menopause (GSM)

The phase III placebo-controlled RCT supporting FDA approval of prasterone enrolled over 400 postmenopausal women with moderate-to-severe dyspareunia. After 12 weeks of daily 6.5 mg vaginal DHEA, women experienced statistically significant improvements in:

• The percentage of superficial vaginal cells (a marker of estrogenization)
• Vaginal pH (reduced from a mean of approximately 6.1 to 5.5)
• Dyspareunia severity rated by participants on a four-point scale
• Vaginal dryness scores

The study found improvement in the most bothersome symptom of dyspareunia was statistically significantly greater than placebo across all four co-primary endpoints. The treatment effect was clinically meaningful, not just statistically detectable.

What Estradiol Gel Does for GSM

Systemic estradiol from gel formulations does improve vaginal tissue. Estrogen receptors in vaginal epithelium respond to rising serum estradiol, increasing cell maturation, lubrication, and reducing pH. However, some women on systemic estradiol gel still have residual vaginal symptoms and require a local vaginal therapy added to their regimen. This is documented in ACOG Practice Bulletin guidance on genitourinary syndrome of menopause, which notes that systemic therapy alone is sometimes insufficient for vaginal symptoms.

Summary: Who Responds Best to Each

| Symptom | Estradiol Gel Evidence | Intrarosa Evidence | |---|---|---| | Hot flashes | Strong, dose-dependent | None (not indicated) | | Night sweats | Strong | None | | Vaginal dryness | Moderate (systemic effect) | Strong (local primary endpoint) | | Dyspareunia | Moderate | Strong (FDA co-primary endpoint) | | Mood/sleep/cognition | Some evidence | Not studied | | Bone density | Yes (systemic estrogen) | No direct data | | Libido | Indirect (via E2) | Possible (local T component) |

Sex-Specific Physiology: How Your Hormonal Life Stage Changes Everything

Perimenopause

During perimenopause, estrogen levels fluctuate wildly rather than declining steadily. A woman in late perimenopause may have estradiol levels anywhere from 20 to over 400 pg/mL across a single month. Estradiol gel can be harder to dose precisely in this context because erratic endogenous production complicates the target range.

Intrarosa is not typically started in perimenopause because the vaginal changes of GSM generally do not become symptomatic until after menstrual cycles have fully stopped. Vaginal pH below 4.5 is usually maintained by lactobacilli during reproductive years, even with irregular cycles.

Post-Menopause

This is the primary target population for both drugs. Post-menopause is defined as 12 or more consecutive months without a period not explained by other causes. Serum FSH is typically above 40 mIU/mL and estradiol below 20 pg/mL. Both therapies have their strongest evidence base in this group.

For a post-menopausal woman with an intact uterus:

• Estradiol gel requires a progestogen (oral progesterone, levonorgestrel IUD, or other) to prevent endometrial hyperplasia.
• Intrarosa does not require progestogen co-administration, because serum estradiol exposure is not sufficient to stimulate the endometrium meaningfully. The Menopause Society position supports this approach for low-dose local therapies.

Surgical Menopause

Women who have had bilateral oophorectomy before natural menopause experience a more abrupt and often more severe drop in both estrogen and testosterone. These women may benefit more from estradiol gel because the systemic dose can be titrated to address vasomotor symptoms that are often more severe after surgical menopause. The local androgen effect of prasterone may also be appealing given the loss of ovarian testosterone production, though data comparing outcomes specifically in this group are sparse.

Safety and Side Effects

Estradiol Gel: What to Watch For

The most clinically significant risks of systemic estrogen therapy are endometrial hyperplasia (when used without progestogen in an intact uterus), and the theoretical cardiovascular and VTE risks that are route-dependent.

The BMJ study of over 80,000 women (Vinogradova et al., 2019) provides the clearest current evidence: transdermal estradiol did not significantly increase VTE risk. This is mechanistically explained by avoiding first-pass hepatic effects on clotting factors, C-reactive protein, and sex hormone-binding globulin.

Common side effects of estradiol gel include:

• Application-site reactions (redness, irritation)
• Breast tenderness, especially in the first 3 months
• Bloating or fluid retention at higher doses
• Spotting or irregular bleeding if progestogen is not adequately dosed

Transferring estradiol gel to others through skin contact is a real risk. Apply to an area covered by clothing (inner thigh or upper arm per product label), let dry fully, and wash hands.

Intrarosa: What to Watch For

Because systemic absorption is minimal, Intrarosa has a more limited systemic side-effect profile. The most common complaints in clinical trials were vaginal discharge (reported by about 14 percent of participants) and minor application discomfort.

The absence of meaningful systemic estrogen means Intrarosa does not protect bones, does not reduce hot flashes, and does not carry the same uterine stimulation concerns. Women on Intrarosa who develop vaginal bleeding should report it, as any post-menopausal bleeding requires evaluation regardless of the therapy used.

Pregnancy, Lactation, and Contraception: Required Reading

Both estradiol gel and Intrarosa are contraindicated in pregnancy.

Estradiol Gel in Pregnancy

Exogenous estrogens should not be used during pregnancy. Animal data show fetal harm at high estrogen exposures. While transdermal estradiol at menopause doses has not been specifically studied in human pregnancy outcomes, there is no clinical indication for its use in a pregnant woman, and it should be stopped immediately if pregnancy is confirmed.

If you are in perimenopause and still having cycles, do not assume you cannot conceive. Spontaneous pregnancy remains possible during perimenopause until 12 full months without a period have passed. If you are using estradiol gel and have not reached confirmed menopause, reliable contraception is required.

The FDA labeling for Divigel lists pregnancy as a contraindication.

Intrarosa in Pregnancy

DHEA and its downstream metabolites cross biological barriers. Intrarosa is contraindicated in pregnancy. No adequate data exist in pregnant women. The drug should not be used by anyone who is or may become pregnant.

Lactation

Neither estradiol gel nor Intrarosa has established safety data in breastfeeding. Estrogen is known to suppress lactation, particularly at systemic doses. Women who are postpartum and breastfeeding should not use estradiol gel. Intrarosa is not indicated in reproductive-age women and has not been studied in lactating women.

Contraception Note

Women in perimenopause using estradiol gel who still have any possibility of ovulation should use non-hormonal or progestogen-only contraception, or discuss combined options with their prescriber. Hormonal contraceptives (combined estrogen-progestin pills) are not typically appropriate alongside prescription estradiol gel due to overlapping systemic estrogen.

Conditions Where One Drug May Fit Better

PCOS

Women with PCOS entering perimenopause often have complex hormonal backgrounds including residual androgen excess, insulin resistance, and sometimes longer-than-average reproductive windows. Estradiol gel is the more standard choice for vasomotor symptoms. Intrarosa adds local androgen activity; while not studied in PCOS-specific menopausal cohorts, the androgen component warrants discussion with your prescriber if androgen-sensitive conditions are part of your history.

History of Hormone-Sensitive Cancer

Neither therapy is approved for use in women with a history of estrogen-receptor-positive breast cancer. ACOG and the Menopause Society recommend non-hormonal options as first-line for these women. For GSM specifically, vaginal lubricants and moisturizers are the starting point, with low-dose local estrogen or prasterone considered only after oncology consultation. The minimal systemic absorption of Intrarosa has prompted some oncologists to permit its use, but this is a case-by-case decision.

Hypoactive Sexual Desire Disorder (HSDD)

Intrarosa's local testosterone component has generated interest in whether it improves libido beyond vaginal comfort. The prasterone RCT did not use HSDD as a primary endpoint, and evidence is insufficient to recommend Intrarosa specifically for HSDD. Vyleesi (bremelanotide) and Addyi (flibanserin) remain the only FDA-approved treatments for HSDD in premenopausal and postmenopausal women respectively.

Osteoporosis Risk

Estradiol gel, as a systemic therapy, provides bone-protective effects. Estrogen maintains bone density by suppressing osteoclast activity. Prasterone has not demonstrated bone-protective effects in clinical trials, given the minimal systemic conversion. Women with osteoporosis or significant osteopenia should factor this into their choice.

Who This Is Right For (and Who It Is Not)

Estradiol Gel Is Likely Right for You If

• You have moderate-to-severe hot flashes or night sweats as your primary complaint
• You are comfortable with systemic hormone therapy and have discussed your personal risk profile
• You have an intact uterus and are able to add a progestogen
• You also want bone protection from your hormone therapy
• You are in perimenopause or post-menopause

Estradiol Gel Is Not the First Choice If

• Your only symptom is vaginal dryness or painful sex, and you prefer to avoid systemic hormone exposure
• You have a personal or strong family history of VTE or cardiovascular disease (though transdermal route is lower risk than oral)
• You have an estrogen-receptor-positive cancer history (contraindicated without specialist guidance)

Intrarosa Is Likely Right for You If

• Painful intercourse (dyspareunia) or vaginal dryness is your primary complaint
• You prefer to avoid systemic estrogen
• You have an intact uterus and do not want to add a progestogen
• You are post-menopausal and your vasomotor symptoms are mild or have resolved

Intrarosa Is Not the First Choice If

• You have significant hot flashes or night sweats
• You want bone-protective effects from your therapy
• You are not yet post-menopausal (not an approved indication)
• You have a history of hormone-sensitive cancer (needs oncology input)

Practical Dosing and Use

Estradiol Gel: How to Use It

Divigel comes in unit-dose packets (0.25 g, 0.5 g, 0.75 g, 1.0 g) delivering 0.25 mg to 1.0 mg estradiol. The gel is applied once daily to the upper thigh (alternate thighs). Elestrin delivers 0.52 mg estradiol per 0.87 g pump actuation to the upper arm.

Start at the lowest dose and titrate based on symptom response and serum estradiol levels. The Menopause Society recommends the lowest effective dose for the shortest appropriate duration, though "shortest duration" is individualized and many women use systemic HT for years.

Intrarosa: How to Use It

One 6.5 mg prasterone vaginal insert is placed using the provided applicator daily at bedtime. This is consistent in all women regardless of body weight. No dose titration is required. Use is continuous; the clinical trials used 12 weeks as the primary endpoint duration, but real-world use extends to years for ongoing GSM management.

The Evidence Gap: What We Do Not Know About Women Specifically

Women were historically under-represented in cardiovascular and hormone safety trials. Most estradiol gel pharmacokinetic data come from predominantly White postmenopausal women. Data on gel use in women of color, women with PCOS entering menopause, or women with surgical menopause are limited.

For Intrarosa, the phase III trial enrolled women who were on average 59 years old. Outcomes in women under 52 (early surgical menopause), in women with prior breast cancer, or in women of diverse racial and ethnic backgrounds have not been studied in adequately powered sub-groups. This matters for generalizability.

The absence of a direct head-to-head trial is not a minor gap. Without one, clinicians and patients must rely on indirect comparisons across trials with different populations, primary endpoints, and follow-up durations. Any content that claims a definitive winner between these two drugs is extrapolating beyond available data.

Switching Between Therapies

Some women start with Intrarosa for vaginal symptoms and later develop significant hot flashes that require adding or switching to systemic estradiol gel. This is a common clinical trajectory.

Switching from systemic estradiol gel to Intrarosa (for example, because a woman has resolved her vasomotor symptoms and only wants local GSM coverage) can generally be done without a washout period, though individual prescribers may manage this differently based on symptom burden.

Women with an intact uterus switching from estradiol gel to Intrarosa can often discontinue their progestogen, because Intrarosa does not require endometrial protection. This should be confirmed with your prescriber based on individual history.

Switching from Intrarosa to estradiol gel requires adding a progestogen if the uterus is intact. The estradiol gel will need time (typically 4 to 8 weeks) to reach steady-state serum levels before full symptom relief is expected.

Frequently Asked Questions